SIGA TPOXX Federal Award Ledger — Smallpox Countermeasure Channel (2006-2029)
mechanismMoney & Finance
Two contracts for the same smallpox pill. One says no competition was held. The other says it was open to all. Both drew one bidder.
Who they are
The federal buying channel for TPOXX, the smallpox antiviral made by SIGA Technologies[1].
What they do
The engine records this as the money route itself, rather than as a claim about the company.
How it works
2011: $518,482,778, marked not competed, only one source, with a rule cited allowing them to skip competition. 2018: $626,506,870, marked open to competition, no exemption claimed — and still one bidder. Across eleven contracts the government has paid SIGA $1,248,133,170, and $1,184,254,053 of that came from the preparedness office. The 2018 deal runs to 2029.
Why it matters
The engine reads the 2011 paperwork as a written carve-out from a stated rule. The 2018 one arrives at the same place with the competitive label intact — why only one company bid is not in the record, and is left open. No claim is made that anyone arranged it.
The engine's record — word for word
Federal procurement channel through which the United States buys tecovirimat (TPOXX), the smallpox antiviral, from SIGA Technologies. The 2011 award, HHSO100201100001C, obligated $518,482,778 and is recorded as NOT COMPETED, solicitation procedure ONLY ONE SOURCE, justified under FAR 6.302-3 (Mobilization, Essential R&D), with one offer received.[1] The 2018 award, 75A50118C00019, obligated $626,506,870 and is recorded as FULL AND OPEN COMPETITION with no other-than-full-and-open justification — and with one offer received.[2] SIGA describes the same 2018 contract, numbered HHSO100201800019C, as worth up to $629 million for oral and intravenous TPOXX delivered to the Strategic National Stockpile, over a five-year base period extendable to ten.[3] Across eleven federal prime awards SIGA has been obligated $1,248,133,170, of which $1,184,254,053 was awarded by the Office of the Assistant Secretary for Preparedness and Response.[4] The 2018 award runs to 30 August 2029, extending the channel a decade beyond the award date.[5] **Engine reading:** the two awards carry opposite competition labels and the same recorded outcome — one offer. The 2011 instrument is a codified exemption in the sense reg_capture names: an announced rule (competitive procurement) decoupled from operating reality by a written carve-out, here the FAR 6.302-3 citation. The 2018 instrument reaches the same single-supplier position while carrying the competitive label and no carve-out on its face; whether that reflects an absent second manufacturer, a shaped solicitation, or something else is NOT in the award record and is held open. Structurally homologous to fed_smccf_blackrock_no_bid_2020, where an optical-conflict mitigation (the ETF Revenue Offset clause) preserved the underlying structural advantage. Apex Superposition: (b) structural-recurrence load-bearing — the codified-exemption fork per the 2026-05-27 weighting update, a guaranteed-market architecture authored by BioShield and PAHPA operating as designed; (c) collective-psychology operative — the competitive label absorbs the procurement-integrity objection while the single-supplier substrate is unchanged; (a) intentional-cabal NOT supported — nothing in the award record evidences orchestration, and no holder is named.
Follow the trail
Walk this on the live map →